Back to Companies
Braveheart Bio, Inc.
BRVENasdaqCIK: 0002131524
Recent Form 4 activity at Braveheart Bio, Inc. (BRVE) spans 29 filings across 15 insiders (all of them on the buy side). Purchases total $159.0M against $0 in sales — heavily weighted toward buying, for a net purchase of $159.0M. Forbion Growth Opportunities Fund III Cooperatief U.A. is the most active by dollar volume, and the single largest transaction was $64.8M by Forbion Growth Opportunities Fund III Cooperatief U.A.. All figures are drawn from official SEC Form 3, 4, and 5 disclosures and update as new filings arrive.
Total Volume
$184.5M
Purchases
$159.0M
Sales
$0
Unique Insiders
15
Recent Insider Trades
29 loaded
| Aug 11 | BRVE Braveheart Bio, Inc. | Chimovits Erez | Director, 10% Owner | Buy | $34.9M |
| Aug 11 | BRVE Braveheart Bio, Inc. | AH Bio Fund IV, L.P. | Insider | Buy | $19.8M |
| Aug 11 | BRVE Braveheart Bio, Inc. | ORBIMED ADVISORS LLC | Director, 10% Owner | Buy | $34.9M |
| Aug 10 | BRVE Braveheart Bio, Inc. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | Conversion | $0 |
| Aug 7 | BRVE Braveheart Bio, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. | Insider | Buy | $64.8M |
| Aug 14 | BRVE Braveheart Bio, Inc. | Agarwala Vineeta | Insider | Other | $0 |
| Aug 6 | BRVE Braveheart Bio, Inc. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | Other | $0 |
| Aug 5 | BRVE Braveheart Bio, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. | Insider | Other | $0 |
| Aug 7 | BRVE Braveheart Bio, Inc. | Malek David I | Director | Buy | $75.0K |
| Aug 5 | BRVE Braveheart Bio, Inc. | Murdoch Travis | CEO and President, Director, 10% Owner | Other | $0 |
| Aug 7 | BRVE Braveheart Bio, Inc. | Murdoch Travis | CEO and President, Director | Buy | $1.5M |
| Aug 5 | BRVE Braveheart Bio, Inc. | Viehbacher Christopher | Director | Other | $0 |
| Aug 7 | BRVE Braveheart Bio, Inc. | Anderson Michele A. | Chief Development Officer | Buy | $20.0K |
| Aug 7 | BRVE Braveheart Bio, Inc. | Viehbacher Christopher | Director | Buy | $1.5M |
| Aug 7 | BRVE Braveheart Bio, Inc. | Lohoff Tim | Director | Award | $540.0K |
| Aug 5 | BRVE Braveheart Bio, Inc. | Lohoff Tim | Director | Other | $0 |
| Aug 5 | BRVE Braveheart Bio, Inc. | Malek David I | Director | Other | $0 |
| Aug 5 | BRVE Braveheart Bio, Inc. | Rickey James Paul | Chief Financial Officer | Other | $0 |
| Aug 5 | BRVE Braveheart Bio, Inc. | Lubner David Charles | Director | Other | $0 |
| Aug 7 | BRVE Braveheart Bio, Inc. | Chimovits Erez | Director, 10% Owner | Award | $540.0K |
| Aug 5 | BRVE Braveheart Bio, Inc. | Chimovits Erez | Director, 10% Owner | Other | $0 |
| Aug 5 | BRVE Braveheart Bio, Inc. | Coloma Jason V | Director | Other | $0 |
| Aug 5 | BRVE Braveheart Bio, Inc. | ORBIMED ADVISORS LLC | Director, 10% Owner | Other | $0 |
| Aug 7 | BRVE Braveheart Bio, Inc. | Rickey James Paul | Chief Financial Officer | Buy | $500.0K |
| Aug 5 | BRVE Braveheart Bio, Inc. | Bos Jasper | Director | Other | $0 |
| Aug 5 | BRVE Braveheart Bio, Inc. | Anderson Michele A. | Chief Development Officer | Other | $0 |
| Aug 7 | BRVE Braveheart Bio, Inc. | Bos Jasper | Director | Award | $540.0K |
| Aug 5 | BRVE Braveheart Bio, Inc. | AH Bio Fund IV, L.P. | Insider | Other | $0 |
| Aug 7 | BRVE Braveheart Bio, Inc. | Lubner David Charles | Director | Buy | $1000.0K |
29 filings